Skip Navigation


Annals of Oncology Advance Access originally published online on February 23, 2006
Annals of Oncology 2006 17(5):763-768; doi:10.1093/annonc/mdl011
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/5/763    most recent
mdl011v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Savoie, M. L.
Right arrow Articles by Lavoie, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Savoie, M. L.
Right arrow Articles by Lavoie, J. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

Shifting to outpatient management of acute myeloid leukemia: a prospective experience

M. L. Savoie*, T. J. Nevil, K. W. Song, D. L. Forrest, D. E. Hogge, S. H. Nantel, J. D. Shepherd, C. A. Smith, H. J. Sutherland, C. L. Toze and J. C. Lavoie

The Leukemia/Bone Marrow Transplant Program of British Columbia, Division of Hematology, Vancouver Hospital Health Sciences Centre, BC Cancer Agency and the University of British Columbia, Vancouver, Canada

* Correspondence to: Dr M. L. Savoie, Room 681, 1403 29th Street NW, Calgary AB, T2N 2T9, Canada. Tel: +011 403 944 1564; Fax: +011 403 944 2102; E-mail: lynn.savoie{at}calgaryhealthregion.ca

Background: We assessed the feasibility of outpatient chemotherapy and supportive care in patients with acute myeloid leukemia (AML).

Patients and methods: All patients receiving curative intent chemotherapy between 09/01 and 10/02 and meeting our criteria received supportive care post induction chemotherapy as well as their entire consolidation chemotherapy cycles as outpatients. Patients received antimicrobial prophylaxis; those developing episodes of fever and not meeting the criteria for admission were treated with outpatient intravenous antibiotics.

Results: Seventy-one cycles of induction chemotherapy were administered for newly diagnosed or relapsed AML. In 25 cycles the patient was discharged post chemotherapy prior to count recovery. Of these, 14 patients developed one or more febrile episodes as an outpatient and nine (36%) required readmission to hospital. Sixty-seven consolidation cycles were given on an outpatient basis. In 39 cycles there was one or more febrile episodes and in 14 (21%) admission was required. Infections were documented in four cases during induction and in 27 during consolidation. There were no treatment-related deaths.

Conclusions: Outpatient management of AML is safe and feasible using the strategies outlined in this report.

Key words: acute myeloid leukaemia, ambulatory, chemotherapy, febrile neutropenia, outpatient, supportive care


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 haematolHome page
R. Naithani, R. Kumar, M. Mahapatra, N. Agrawal, and P. Mishra
Early discharge from hospital after consolidation chemotherapy in acute myeloid leukemia in remission: febrile neutropenic episodes and their outcome in a resource poor setting
Haematologica, September 1, 2008; 93(9): 1416 - 1418.
[Full Text] [PDF]

Home page
 Ann OncolHome page
T. Halim, K. Song, M. Barnett, D. Forrest, D. Hogge, S. Nantel, T. Nevill, J. Shepherd, C. Smith, H. Sutherland, et al.
Positive impact of selective outpatient management of high-risk acute myelogenous leukemia on the incidence of septicemia
Ann. Onc., July 1, 2007; 18(7): 1246 - 1252.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.